UK's Big Picture Bio raises $2M pre-seed to design cancer drug combinations
What's the deal? Big Picture BioDealroom has a profile for this one. Try Dealroom →, a UK biotech using AI to design cancer combination therapies, has closed a £1.5 million ($2 million) pre-seed round. Kadmos CapitalDealroom has a profile for this one. Try Dealroom → and Exceptional VenturesDealroom has a profile for this one. Try Dealroom → co-led, with participation from Gloucester VenturesDealroom has a profile for this one. Try Dealroom → and angel investor John White.
What's the endgame? The company's platform uses a generative world model to map how tumours, immune cells, and surrounding tissue interact across disease sites and patient subgroups. Combined with wet lab validation, it aims to identify drug combinations most likely to work in patients — with cancer and immune-mediated diseases as the initial focus.
Why now? The pre-seed adds to £700,000 in non-dilutive funding from Innovate UKDealroom has a profile for this one. Try Dealroom →, for £2.2 million total. That money takes Big Picture Bio's first designed combinations from in silico design into the lab.
Who's behind it? The company was founded by chief executive officer Kerstin Papenfuss and chief technology officer Mark Hammond, both veterans of Deep Science VenturesDealroom has a profile for this one. Try Dealroom →. Papenfuss founded 12 companies as director of pharma there; Hammond co-founded the firm and led its work in agentic scientific discovery. Advisers include figures from AstraZenecaDealroom has a profile for this one. Try Dealroom →, Exscientia, and PhoreMost.
The proof point: Big Picture Bio says its platform has been validated against real-world clinical outcomes presented at ASCO and correctly predicted the failure of RegeneronDealroom has a profile for this one. Try Dealroom →'s fianlimab trial. It says its models reason from the ground up, making predictions traceable to the underlying biology.
"Cancer is not one disease driven by one target, but we still develop drugs as if it were," Papenfuss said. "With more than 900 billion of them possible, no lab on earth can test its way to the right ones."
The signal: The round is a modest one, sitting in the lower tiers by size, reflecting the early stage of an AI-driven drug discovery bet. But it lands in a sector where investors are increasingly funding computational approaches to narrow the vast space of possible cancer treatments before committing to costly lab work.
Read more: finanznachrichten.de
Image credit: Big Picture Bio
